A new study has highlighted a significant knowledge gap among patients about repeat radiotherapy (reirradiation) as a treatment option for recurrent prostate cancer ...

An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...

Please provide your email address to receive an email when new articles are posted on . All men with BRCA2 mutations treated with olaparib monotherapy achieved at least a 50% decline in PSA. The study ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...